Excretion, biodistribution and pharmacokinetics of the above-mentioned drug after oral doses of 10 and 50 mg/kg were investigated. The drug is completely and rapidly resorbed from the digestive tract. It shows relatively large renal and metabolic clearance, it is extensively distributed in the tissues This results in its rapid elimination from plasma (t1/2 approximately 3 h) and, on the other hand, higher concentrations of radioactive drugs in tissues. Penetration and specific binding of VUFB 15468 in the murine brain in dependence on the administered dose were tested (ED50 approximately 4 mg/kg). Autoradiographic examination of the rat brain demonstrated an increased concentration of radioactive drugs in the cerebral cortex, hippocampus, hypophysis and central ganglia.

01 Jul 1990·Ceskoslovenska farmacie

[Metabolites of substance VUFB 15468 in animals].

Article

Author: Poláková, L ; Sispera, L ; Metysová, J ; Koruna, I ; Ryska, M ; Svátek, E ; Lapka, R

Metabolites of drug VUFB 15468 present in the urine of rats, mice and dogs and in rat faeces after peroral administration were determined qualitatively. The relative representation of the individual metabolites in the urine of rats and mice was determined radiometrically after p. o. administration of [3H]VUFB 15468. For qualitative demonstration the metabolites were extracted; they were detected, partially identified and purified by thin-layer chromatography and then analyzed by mass spectrometry and IR-spectrometry. Structures of 11 metabolites were completely or partially determined in rat urine. Five of them were also found in rat faeces, one in murine urine and five in canine urine. In all animal species also unchanged VUFB 15468 was found. For quantification of the individual metabolites and VUFB 15468, TLC-radiometry and liquid scintillation spectrometry were used in rats and mice. Of the relative representation of metabolites, about one third is unchanged VUFB 15468, the rest are metabolites. In mice, the proportion of unchanged VUFB 15468 is much higher, about two thirds.

100 Deals associated with Moxifetin hydrogen maleate

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Depressive Disorder, Major	Phase 1	-	Spofa As	-
Depressive Disorder, Major	Phase 1	-	Research Institute for Pharmacy and Biochemistry	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Moxifetin hydrogen maleate

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation